MAF Test®
Early-Stage Breast Cancer (Adjuvant Therapy Selection)
Approved/CommercialActive
Key Facts
Indication
Early-Stage Breast Cancer (Adjuvant Therapy Selection)
Phase
Approved/Commercial
Status
Active
Company
About Inbiomotion
Inbiomotion is a private, commercial-stage diagnostics company based in Barcelona, Spain, founded in 2010. Its core asset is the MAF Test®, a prognostic and predictive biomarker test that analyzes MAF gene expression to guide the use of adjuvant bisphosphonates in early breast cancer. The test, which has been included in Spanish clinical guidelines, aims to improve patient selection, prevent ineffective treatment, and reduce the risk of relapse and bone metastasis. The company is addressing a significant unmet need in a large global market but faces risks related to market adoption, reimbursement, and competition.
View full company profile